Spruce Biosciences price target raised to $9 from $8 at RBC Capital

RBC Capital analyst Gregory Renza raised the firm’s price target on Spruce Biosciences to $9 from $8 and keeps an Outperform rating on the shares after meeting with its management head of the CAHmelia-203 and CAHptain-205 topline readouts in March. The firm remains optimistic, with views bolstered by tildacerfont data to-date and the management’s conviction, also noting that its clear points of class differentiation should serve tildacerfont well in the long term, the analyst tells investors in a research note.